Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0075 • ACR Convergence 2020
CD209+/CD14+ Dendritic Cells Characterization in Rheumatoid versus Psoriasis Arthritis Patients
Viviana Marzaioli¹, Achilleas Floudas², Mary Canavan¹, Siobhán Wade³, Kieran Murray⁴, Ronan Mullan⁵, Conor Hurson⁶, Douglas Veale⁷ and Ursula Fearon¹, ¹Molecular Rheumatology, Trinity College Dublin, Dublin, Dublin, Ireland, ²Molecular Rheumatology Trinity Biomedical Sciences Institute, Dublin, Dublin, Ireland, ³Trinity College Dublin, Dublin, Ireland, ⁴Saint Vincent's University Hospital, Dublin 4, Dublin, Ireland, ⁵Adelaide and Meath Hospital, Dublin, Dublin, Ireland, ⁶St Vincents University Hospital, UCD, Dublin, Dublin, Ireland, ⁷EULAR Centre for Arthritis and Rheumatic Diseases, St Vincents University Hospital, UCD, Dublin, Dublin, Ireland
Background/Purpose: Dendritic cells (DCs) are a heterogeneous population of professional antigen-presenting cells which are at the interface between innate and adaptive immunity. There are different…
Abstract Number: 0143 • ACR Convergence 2020
Filgotinib Improved Work Productivity and Activity Impairment in Patients with Rheumatoid Arthritis Who Are Methotrexate-naïve: Results from the FINCH-3 Study
Zobair Younossi¹, Maria Stepanova², Lynn Gerber¹, Susan Lee³, Ken Hasegawa³, Thijs Hendrikx⁴, Annelies Boonen⁵, Bernard Combe⁶, David Walker⁷ and Rieke Alten⁸, ¹Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, VA, ²Center for Outcomes Research in Liver Disease, Washington, DC, ³Gilead Sciences, Inc., Foster City, CA, ⁴Galapagos BV, Leiden, Netherlands, ⁵Maastricht University Medical Center, Maastricht, Netherlands, ⁶University of Montpellier, Montpellier, France, ⁷Northumbria Healthcare Trust, North Shields, United Kingdom, ⁸Schlosspark-Klinik, Universitätsmedizin, Berlin, Germany
Background/Purpose: Filgotinib (FIL) is a potent oral selective janus kinase 1 inhibitor currently being investigated as an agent to treat rheumatoid arthritis (RA). In the…
Abstract Number: 0181 • ACR Convergence 2020
Methotrexate Use Does Not Increase the Prevalence of Hepatic Steatosis: A Real-World Retrospective Nested Case-Control Study
Yunjung Choi¹, Chang-Hun Lee¹, Myeung-Su Lee², Chang-Hoon Lee², SoJeong Park³ and Wan-Hee Yoo⁴, ¹Jeonbuk National University Hospital, Jeonju, Republic of Korea, ²Wonkwang University Hospital, Iksan, Republic of Korea, ³Data Science Team, Hanmi Pharm. Co., Ltd, Seoul, Romania, ⁴Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital, Jeonju, Republic of Korea
Background/Purpose: We aimed to determine whether methotrexate (MTX) treatment in patients with rheumatoid arthritis (RA) leads to the development of nonalcoholic fatty liver (NAFL).Methods: Data…
Abstract Number: 0198 • ACR Convergence 2020
A Prospective Cohort Study of Vehicle Control as a Measure of Driving Performance in Patients with Rheumatoid Arthritis
Kaleb Michaud¹, Jennifer Merickel¹, Yeongjin Gwon¹, Harlan Sayles¹, Haley Kampschnieder¹, Rebecca Hiebert¹, Alison Petro¹, Bryant England¹, Matthew Rizzo¹ and Ted Mikuls¹, ¹University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Automobile driving is an instrumental activity of daily living. Owing to symptoms and functional impairment, patients with rheumatoid arthritis (RA) rely disproportionately on driving…
Abstract Number: 0214 • ACR Convergence 2020
Sustainability of Response Between Upadacitinib and Adalimumab Among Patients with Rheumatoid Arthritis and Prior Inadequate Response to Methotrexate
Peter Nash¹, Arthur Kavanaugh², Maya Buch³, Bernard Combe⁴, Louis Bessette⁵, In-Ho Song⁶, Yanna Song⁷, Jessica Suboticki⁶ and Roy Fleischmann⁸, ¹School of Medicine Griffith University, Brisbane, Queensland, Australia, ²Division of Rheumatology, Allergy, & Immunology, University of California San Diego Medical School, San Diego, CA, ³Centre of Musculoskeletal Research, School of Biological Sciences, University of Manchester, Manchester, United Kingdom, ⁴University of Montpellier, Montpellier, France, ⁵Laval University, Quebec, Canada, ⁶AbbVie Inc., North Chicago, IL, ⁷AbbVie Inc., North Chicago,, IL, ⁸Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: The primary treatment goal for patients(pts) with rheumatoid arthritis(RA) is a state of sustained clinical remission(REM) or low disease activity(LDA).1,2 We assess long-term sustainability…
Abstract Number: 0231 • ACR Convergence 2020
Treatment Patterns of Biologic/Targeted Synthetic DMARDs for the Management of Rheumatoid Arthritis in Australia: An Analysis of the OPAL Dataset
Helen Cooley¹, Tegan Smith², Peter Youssef³, Kathleen Tymms⁴, David Mathers⁵, Sabina Ciciriello⁶, Hedley Griffiths⁷, Catherine OSullivan² and Geoffrey Littlejohn⁸, ¹Hobart Private Hospital, Hobart, TAS, Taroona, Australia, ²OPAL Rheumatology Ltd, Sydney, NSW, Kogarah, New South Wales, Australia, ³University of Sydney, Sydney, NSW; Royal Prince Alfred Hospital, Camperdown, NSW, Camperdown, New South Wales, Australia, ⁴Canberra Rheumatology, Canberra, ACT, Canberra, Australian Capital Territory, Australia, ⁵Georgetown Rheumatology, Georgetown, NSW, Georgetown, New South Wales, Australia, ⁶Royal Melbourne Hospital, Melbourne, VIC, Melbourne, Victoria, Australia, ⁷Barwon Rheumatology Service, Geelong, VIC, Geelong, Victoria, Australia, ⁸Monash Rheumatology, Clayton, VIC; OPAL Rheumatology Ltd, Sydney, NSW, Melbourne, Victoria, Australia
Background/Purpose: In Australia the cost of biological/targeted synthetic DMARDs (b/tsDMARDs) for treatment of RA is subsidized if the patient has documented high levels of clinical/laboratory…
Abstract Number: 0451 • ACR Convergence 2020
Prevalence, Therapy and Tumor Response in Patients with Rheumatic Immune-related Adverse Events Following Immune Checkpoint Inhibitor Therapy: A Single-Centre Analysis
Sophia Verspohl¹, Tobias Holderried¹, Charlotte Behning², Peter Brossart¹ and Valentin Schaefer³, ¹Clinic for Internal Medicine III, Department of Oncology, Hematology and Rheumatology, University Hospital Bonn, Germany, Bonn, Nordrhein-Westfalen, Germany, ²Institute for Medical Biometrics, Informatics and Epidemiology (IMBIE), University Hospital Bonn, Bonn, Germany, Bonn, Nordrhein-Westfalen, Germany, ³Clinic of Internal Medicine III, Department of Oncology, Hematology and Rheumatology, University Hospital Bonn, Germany, Bonn, Nordrhein-Westfalen, Germany
Background/Purpose: Immune checkpoint inhibitors (ICIs) have improved cancer therapy [1] by inducing a higher immune system activity and subsequent attack of tumor cells. However, this effect…
Abstract Number: 0491 • ACR Convergence 2020
Relationship Between Rheumatoid Arthritis and Pulmonary Function in the UK Biobank
Lauren C. Prisco¹, Matthew Moll¹, Jiaqi Wang², Weixing Huang³, Lily Martin¹, Vanessa Kronzer⁴, Sicong Huang², Edwin Silverman², Tracy J. Doyle⁵, Michael Cho⁵ and Jeffrey Sparks⁶, ¹Brigham and Women's Hospital, Boston, ²Brigham and Women's Hospital, Boston, MA, ³Division of Rheumatology, Inflammation, and Immunity; Brigham and Women’s Hospital and Harvard Medical School, Boston, ⁴Mayo Clinic, Rochester, MN, ⁵Brigham and Women's Hospital, West Roxbury, MA, ⁶Division of Rheumatology, Inflammation, and Immunity; Brigham and Women’s Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Established pulmonary manifestations of RA include restrictive processes such as interstitial lung disease and obstructive processes such as bronchiectasis, but clinically detected forms of…
Abstract Number: 0698 • ACR Convergence 2020
Baseline Factors Are Not Associated with Rehabilitation Dose over Six Months Among Adults with RA
Louise Thoma¹, Elizabeth Wellsandt², Kristin Wipfler³ and Kaleb Michaud², ¹University of North Carolina at Chapel Hill, Chapel Hill, NC, ²University of Nebraska Medical Center, Omaha, NE, ³FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE
Background/Purpose: Functional limitation is common in adults with rheumatoid arthritis (RA). Rehabilitation services, like physical therapy (PT) and occupational therapy (OT), are effective in improving…
Abstract Number: 0756 • ACR Convergence 2020
Increased Risk of Hospitalization in Patients with RA Who Are ACPA Positive and Shared Epitope Positive
Joe Zhuo¹, Manasi Suryavanshi¹, Lawshia Priya², Vadim Khaychuk¹, John Vaile¹, Jing Cui³, Nancy Shadick⁴ and Michael Weinblatt³, ¹Bristol-Myers Squibb Company, Princeton, NJ, ²Mu-Sigma, Bangalore, India, ³Brigham and Women's Hospital, Boston, MA, ⁴Division of Rheumatology, Inflammation, and Immunity; Brigham and Women’s Hospital and Harvard Medical School, Boston, MA
Background/Purpose: A strong genetic association between HLA-DRB1 alleles containing the shared epitope (SE) and RA has been described.1 The SE has been associated with ACPA…
Abstract Number: 0774 • ACR Convergence 2020
Nr4a1-high Arthritogenic T Cells from SKG Mice Are Associated with Markers of Recent and Chronic Antigen-stimulation and an Altered T Cell Receptor Repertoire
Judith Ashouri-Sinha¹, Elizabeth McCarthy¹, Steven Yu², Chun Jimmie Ye¹ and Arthur Weiss¹, ¹UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, San Francisco, CA, ²UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, San Francsico, CA
Background/Purpose: T cells can either be activated through their T cell receptor (TCR) in an antigen-specific manner, or in response to cytokines. Identification of antigen-reactive…
Abstract Number: 0791 • ACR Convergence 2020
Peficitinib Inhibits Angiogenesis via Suppression of VEGF Production in Rheumatoid Arthritis Fibroblast-like Synoviocytes
Yuzo Ikari¹, Takeo Isozaki¹, Kuninobu Wakabayashi¹ and Tsuyoshi Kasama², ¹Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan, ²Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Koutou-ku Tokyo, Japan
Background/Purpose: Peficitinib is a novel Janus kinase (JAK) inhibitor developed for the treatment of rheumatoid arthritis (RA). Peficitinib has approved in 2019 in Japan, but…
Abstract Number: 0807 • ACR Convergence 2020
Safety of Biologic & Targeted Therapies Among Elderly Patients with Rheumatoid Arthritis: A Systematic Review and Meta-analysis
Akhil Sood¹, Soham Al Snih¹, Vijaya Murthy², Emilio Gonzalez¹ and Mukaila Raji¹, ¹University of Texas Medical Branch, Galveston, TX, ²University of Texas Medical Branch, League City, TX
Background/Purpose: Recent developments in biologic and targeted therapy have led to better control of disease activity and improved quality of life in patients with rheumatoid…
Abstract Number: 0824 • ACR Convergence 2020
The Comparative Effectiveness of Abatacept versus Tofacitinib After 6 Months of Treatment in Patients with RA Who Were Anti-citrullinated Protein Antibody Positive at Baseline: Results from a US National Observational Study
Leslie Harrold¹, Keith Wittstock², Sheila Kelly², Xue Han², Ying Shan¹, Page Moore¹, Lin Guo¹ and Vadim Khaychuk², ¹Corrona, LLC, Waltham, MA, ²Bristol-Myers Squibb Company, Princeton, NJ
Background/Purpose: Previous data from the Corrona RA registry, conducted in a US clinical practice setting, demonstrated that patients (pts) with RA who were ACPA+ had…
Abstract Number: 0967 • ACR Convergence 2020
Absence of Thy1 Associated with Severe Bone Loss in the TNF-transgenic (TNF-Tg) Mice Arthritis Model
Ananta Paine¹, Maria de la Luz Garcia-Hernandez², Marc Nuzzo³, Stacey Duemmel³, Benjamin Korman¹ and Christopher Ritchlin¹, ¹Department of Medicine, University of Rochester Medical Center, Rochester, NY, ²Department of Medicine, University of Rochester Medical Center, West Henrietta, NY, ³Department of Medicine, University of Rochester Medical Center, Rochester
Background/Purpose: Thy1 (CD90) is a glycosylated, glycophosphatidylinositol (GPI)-anchored membrane protein noted to be expressed on many cells including T lymphocytes, stem cells, osteoblasts and fibroblasts.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].